Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018
Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.
Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy and safety of doxercalciferol (1α hydroxyvitamin DFrontiers in endocrinology · 2026Trial
- Combination of Calcitriol and Zoledronic Acid on PINP andDisease markers · 2022Trial
- Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis.Journal of bone and mineral metabolism · 2020Trial
- Comparison of Efficacy and Safety of Denosumab with Eldecalcitol or Native Vitamin D in Postmenopausal Chinese Women with Osteoporosis (ESCORT): A Randomized Controlled Trial.Journal of clinical medicine · 2026Article
- Combined vitamin KScientific reports · 2025Article
- Elucidating common biomarkers and pathways of osteoporosis and aortic valve calcification: insights into new therapeutic targets.Scientific reports · 2024Article
- A pharmacovigilance study on clinical factors of active vitamin DScientific reports · 2024Article
- Effects of vitamin D supplementation on muscle strength in middle-aged and elderly individuals: a retrospective, propensity score-matched study.Frontiers in nutrition · 2024Article
- A long non-coding RNA as a direct vitamin D target transcribed from the antisense strand of the human HSD17B2 locus.Bioscience reports · 2022Article
- Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study.Journal of bone and mineral metabolism · 2022Article
- The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis.International journal of molecular sciences · 2021Review
- Serum 25-hydroxyvitamin D concentrations in Japanese postmenopausal women with osteoporotic fractures.Osteoporosis and sarcopenia · 2019Article
- The Function of the Vitamin D Receptor and a Possible Role of Enhancer RNA in Epigenomic Regulation of Target Genes: Implications for Bone Metabolism.Journal of bone metabolism · 2019Review
- Glutathione depleting drugs, antioxidants and intestinal calcium absorption.World journal of gastroenterology · 2018Review
- Efficacy of Danshen injection combined with Calcitriol and Calcium/Vitamin-D for the treatment of osteoporotic fractures: A retrospective case-control study.Pakistan journal of medical sciencesArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal fractional calcium absorption (FCA) was assessed before and after vitamin D3 treatment. Serum 1,25(OH)
introductionTo assess the effects of vitamin D3 compounds on intestinal FCA and calcium-regulating hormones in post-menopausal osteoporosis, a randomized open-label prospective study was conducted.
methodsForty eligible patients were allocated randomly into four groups: eldecalcitol (ELD; 0.75 μg/day), 1α hydroxyl calcidiol (ALF; 1 μg/day), plain vitamin D3 (800 IU/day), and control. Before and after the 4-week treatment, intestinal FCA was estimated by using a double isotope method, and serum concentrations of calcium-regulating hormones and a bone turnover marker were measured.
resultsThe baseline FCA value of the participants was 21.5 ± 7.9% (mean ± SD) and was significantly correlated with serum 1,25(OH)
conclusionThese findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not. Those effects of vitamin D3 compounds on FCA were independent of serum calcitriol concentration, suggesting that ALF and ELD may directly stimulate intestinal vitamin D receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.